Brief: Sellas Life Sciences Gets Positive Recommendation For Galinpepimut-S In Acute Myeloid Leukemia
04/12/2023 14:22
Dec 4 (Reuters) - Sellas Life Sciences Group SLS.O :
* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE RECOMMENDATION
FROM
REGAL INDEPENDENT DATA MONITORING COMMITTEE OF GALINPEPIMUT-S IN
ACUTE MYELOID LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC - IDMC WILL REVIEW MOST
CURRENT
SURVIVAL DATA AT NEXT SCHEDULED IDMC MEETING IN Q1 2024
* SELLAS LIFE SCIENCES GROUP - INDEPENDENT DATA MONITORING
COMMITTEE (IDMC) RECOMMENDED CONTINUATION OF PHASE 3 REGAL TRIAL
WITHOUT ANY MODIFICATIONS
Source text for Eikon: ID:nGNX7YKdHk
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses